In this Q&A with Pharmacy Times, Joanne Mortimer, MD, FACP, FASCO, discusses emerging evidence on the safety and potential benefits of GLP-1 receptor agonists (RAs) in women with breast cancer. Mortimer explains that available data show no…
GLP-1 Agonists May Favorably Influence Metabolic Risk and Breast Cancer Outcomes
